Israel - English - Ministry of Health

takeda israel ltd - brentuximab vedotin - powder for concentrate for solution for infusion - brentuximab vedotin 50 mg/vial - brentuximab vedotin - adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl): 1. following autologous stem cell transplant (asct) or 2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following asct. adcetris is indicated for the treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy . adcetris is indicated for the treatment of adult patients with previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine.adcetris is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 30 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 90 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.